Efficacy of Residual Site Radiation Therapy (ISRT) in Patients with Primary Mediastinal Lymphoma with Deauville Score 4 Following R-CHT: Results of a Retrospective Mono Institutional Study
Background: In order to evaluate the efficacy of residual site radiation therapy (RSRT) in terms of progression-free survival (PFS) and overall survival (OS) in patients with primary mediastinal lymphoma (PMBCL) with Deauville Score 4 (DS 4) following rituximab and chemotherapy treatment (R-ICHT). M...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-05-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/12/11/3777 |
| _version_ | 1797597206170042368 |
|---|---|
| author | Giuseppe Facondo Mattia Serio Gianluca Vullo Maria Paola Bianchi Sabrina Pelliccia Alice Di Rocco Tiziana Lanzolla Maurizio Valeriani Arianna Di Napoli Agostino Tafuri Maurizio Martelli Mattia Falchetto Osti Vitaliana De Sanctis |
| author_facet | Giuseppe Facondo Mattia Serio Gianluca Vullo Maria Paola Bianchi Sabrina Pelliccia Alice Di Rocco Tiziana Lanzolla Maurizio Valeriani Arianna Di Napoli Agostino Tafuri Maurizio Martelli Mattia Falchetto Osti Vitaliana De Sanctis |
| author_sort | Giuseppe Facondo |
| collection | DOAJ |
| description | Background: In order to evaluate the efficacy of residual site radiation therapy (RSRT) in terms of progression-free survival (PFS) and overall survival (OS) in patients with primary mediastinal lymphoma (PMBCL) with Deauville Score 4 (DS 4) following rituximab and chemotherapy treatment (R-ICHT). Methods: Thirty-one patients with PMBCL were recruited. After completion of R-ICHT, patients were staged with 18F-fluorodeoxyglucose positron-emission tomography, showing DS 4, and were treated with adjuvant RSRT. The chosen techniques for RT delivery were intensity-modulated radiation therapy (IMRT) or three-dimensional conformal RT (3D-CRT). Most patients underwent the first one using cone-beam computed tomography (CBCT). All patients were evaluated every 3 months for the first 2 years and every 6 months afterwards for a period of at least 5 years, with clinical and radiological procedures as required. Results: All patients received RSRT with a dose of 30 Gy in 15 fractions. The median follow-up time of 52.7 months (IQR: 26–64.1 months). The 5-year OS rate was 100%. The 2-year and 5-year PFS rates were 96.7% and 92.5%, respectively. Patients with relapsed disease had been treated with high-dose chemotherapy (HDC) and autologous stem cell transplantation (auto-SCT). Conclusion: RSRT in patients with PMBCL treated with ICHT and DS 4 did not impact unfavorably on patient survival. |
| first_indexed | 2024-03-11T03:03:22Z |
| format | Article |
| id | doaj.art-2b09b621a72a45aa976c24bf175a5ea8 |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-11T03:03:22Z |
| publishDate | 2023-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-2b09b621a72a45aa976c24bf175a5ea82023-11-18T08:06:17ZengMDPI AGJournal of Clinical Medicine2077-03832023-05-011211377710.3390/jcm12113777Efficacy of Residual Site Radiation Therapy (ISRT) in Patients with Primary Mediastinal Lymphoma with Deauville Score 4 Following R-CHT: Results of a Retrospective Mono Institutional StudyGiuseppe Facondo0Mattia Serio1Gianluca Vullo2Maria Paola Bianchi3Sabrina Pelliccia4Alice Di Rocco5Tiziana Lanzolla6Maurizio Valeriani7Arianna Di Napoli8Agostino Tafuri9Maurizio Martelli10Mattia Falchetto Osti11Vitaliana De Sanctis12Department of Medicine and Surgery and Translational Medicine, Sapienza University of Rome, Radiotherapy Oncology, St. Andrea Hospital, 00189 Rome, ItalyDepartment of Medicine and Surgery and Translational Medicine, Sapienza University of Rome, Radiotherapy Oncology, St. Andrea Hospital, 00189 Rome, ItalyDepartment of Medicine and Surgery and Translational Medicine, Sapienza University of Rome, Radiotherapy Oncology, St. Andrea Hospital, 00189 Rome, ItalyHematology Institute, Sapienza University of Rome, St. Andrea Hospital, 00189 Rome, ItalyHematology Institute, Sapienza University of Rome, St. Andrea Hospital, 00189 Rome, ItalyDepartment of Translational and Precision Medicine, Hematology Institute, Sapienza University of Rome, Umberto I, 00189 Rome, ItalyNuclear Medicine Unit, Department of Medical-Surgical Sciences and Translational Medicine, Sapienza University of Rome, St. Andrea Hospital, 00189 Rome, ItalyDepartment of Medicine and Surgery and Translational Medicine, Sapienza University of Rome, Radiotherapy Oncology, St. Andrea Hospital, 00189 Rome, ItalyPathology Unit, Department of Clinical and Molecular Medicine, Sapienza University of Rome, St. Andrea Hospital, 00189 Rome, ItalyDepartment of Translational and Precision Medicine, Hematology Institute, Sapienza University of Rome, Umberto I, 00189 Rome, ItalyDepartment of Translational and Precision Medicine, Hematology Institute, Sapienza University of Rome, Umberto I, 00189 Rome, ItalyDepartment of Medicine and Surgery and Translational Medicine, Sapienza University of Rome, Radiotherapy Oncology, St. Andrea Hospital, 00189 Rome, ItalyDepartment of Medicine and Surgery and Translational Medicine, Sapienza University of Rome, Radiotherapy Oncology, St. Andrea Hospital, 00189 Rome, ItalyBackground: In order to evaluate the efficacy of residual site radiation therapy (RSRT) in terms of progression-free survival (PFS) and overall survival (OS) in patients with primary mediastinal lymphoma (PMBCL) with Deauville Score 4 (DS 4) following rituximab and chemotherapy treatment (R-ICHT). Methods: Thirty-one patients with PMBCL were recruited. After completion of R-ICHT, patients were staged with 18F-fluorodeoxyglucose positron-emission tomography, showing DS 4, and were treated with adjuvant RSRT. The chosen techniques for RT delivery were intensity-modulated radiation therapy (IMRT) or three-dimensional conformal RT (3D-CRT). Most patients underwent the first one using cone-beam computed tomography (CBCT). All patients were evaluated every 3 months for the first 2 years and every 6 months afterwards for a period of at least 5 years, with clinical and radiological procedures as required. Results: All patients received RSRT with a dose of 30 Gy in 15 fractions. The median follow-up time of 52.7 months (IQR: 26–64.1 months). The 5-year OS rate was 100%. The 2-year and 5-year PFS rates were 96.7% and 92.5%, respectively. Patients with relapsed disease had been treated with high-dose chemotherapy (HDC) and autologous stem cell transplantation (auto-SCT). Conclusion: RSRT in patients with PMBCL treated with ICHT and DS 4 did not impact unfavorably on patient survival.https://www.mdpi.com/2077-0383/12/11/3777lymphomaprimary mediastinal lymphomaradiotherapyresidual site radiation therapy |
| spellingShingle | Giuseppe Facondo Mattia Serio Gianluca Vullo Maria Paola Bianchi Sabrina Pelliccia Alice Di Rocco Tiziana Lanzolla Maurizio Valeriani Arianna Di Napoli Agostino Tafuri Maurizio Martelli Mattia Falchetto Osti Vitaliana De Sanctis Efficacy of Residual Site Radiation Therapy (ISRT) in Patients with Primary Mediastinal Lymphoma with Deauville Score 4 Following R-CHT: Results of a Retrospective Mono Institutional Study Journal of Clinical Medicine lymphoma primary mediastinal lymphoma radiotherapy residual site radiation therapy |
| title | Efficacy of Residual Site Radiation Therapy (ISRT) in Patients with Primary Mediastinal Lymphoma with Deauville Score 4 Following R-CHT: Results of a Retrospective Mono Institutional Study |
| title_full | Efficacy of Residual Site Radiation Therapy (ISRT) in Patients with Primary Mediastinal Lymphoma with Deauville Score 4 Following R-CHT: Results of a Retrospective Mono Institutional Study |
| title_fullStr | Efficacy of Residual Site Radiation Therapy (ISRT) in Patients with Primary Mediastinal Lymphoma with Deauville Score 4 Following R-CHT: Results of a Retrospective Mono Institutional Study |
| title_full_unstemmed | Efficacy of Residual Site Radiation Therapy (ISRT) in Patients with Primary Mediastinal Lymphoma with Deauville Score 4 Following R-CHT: Results of a Retrospective Mono Institutional Study |
| title_short | Efficacy of Residual Site Radiation Therapy (ISRT) in Patients with Primary Mediastinal Lymphoma with Deauville Score 4 Following R-CHT: Results of a Retrospective Mono Institutional Study |
| title_sort | efficacy of residual site radiation therapy isrt in patients with primary mediastinal lymphoma with deauville score 4 following r cht results of a retrospective mono institutional study |
| topic | lymphoma primary mediastinal lymphoma radiotherapy residual site radiation therapy |
| url | https://www.mdpi.com/2077-0383/12/11/3777 |
| work_keys_str_mv | AT giuseppefacondo efficacyofresidualsiteradiationtherapyisrtinpatientswithprimarymediastinallymphomawithdeauvillescore4followingrchtresultsofaretrospectivemonoinstitutionalstudy AT mattiaserio efficacyofresidualsiteradiationtherapyisrtinpatientswithprimarymediastinallymphomawithdeauvillescore4followingrchtresultsofaretrospectivemonoinstitutionalstudy AT gianlucavullo efficacyofresidualsiteradiationtherapyisrtinpatientswithprimarymediastinallymphomawithdeauvillescore4followingrchtresultsofaretrospectivemonoinstitutionalstudy AT mariapaolabianchi efficacyofresidualsiteradiationtherapyisrtinpatientswithprimarymediastinallymphomawithdeauvillescore4followingrchtresultsofaretrospectivemonoinstitutionalstudy AT sabrinapelliccia efficacyofresidualsiteradiationtherapyisrtinpatientswithprimarymediastinallymphomawithdeauvillescore4followingrchtresultsofaretrospectivemonoinstitutionalstudy AT alicedirocco efficacyofresidualsiteradiationtherapyisrtinpatientswithprimarymediastinallymphomawithdeauvillescore4followingrchtresultsofaretrospectivemonoinstitutionalstudy AT tizianalanzolla efficacyofresidualsiteradiationtherapyisrtinpatientswithprimarymediastinallymphomawithdeauvillescore4followingrchtresultsofaretrospectivemonoinstitutionalstudy AT mauriziovaleriani efficacyofresidualsiteradiationtherapyisrtinpatientswithprimarymediastinallymphomawithdeauvillescore4followingrchtresultsofaretrospectivemonoinstitutionalstudy AT ariannadinapoli efficacyofresidualsiteradiationtherapyisrtinpatientswithprimarymediastinallymphomawithdeauvillescore4followingrchtresultsofaretrospectivemonoinstitutionalstudy AT agostinotafuri efficacyofresidualsiteradiationtherapyisrtinpatientswithprimarymediastinallymphomawithdeauvillescore4followingrchtresultsofaretrospectivemonoinstitutionalstudy AT mauriziomartelli efficacyofresidualsiteradiationtherapyisrtinpatientswithprimarymediastinallymphomawithdeauvillescore4followingrchtresultsofaretrospectivemonoinstitutionalstudy AT mattiafalchettoosti efficacyofresidualsiteradiationtherapyisrtinpatientswithprimarymediastinallymphomawithdeauvillescore4followingrchtresultsofaretrospectivemonoinstitutionalstudy AT vitalianadesanctis efficacyofresidualsiteradiationtherapyisrtinpatientswithprimarymediastinallymphomawithdeauvillescore4followingrchtresultsofaretrospectivemonoinstitutionalstudy |